Figure 4 PET imaging in experimental pancreatic cancer

Slides:

Advertisements

Similar presentations

“From man to mouse” … Human PET microPET human mouse rat rat infant

Advertisements

Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.

16 November 2004Biomedical Imaging BMEN Biomedical Imaging of the Future Alvin T. Yeh Department of Biomedical Engineering Texas A&M University.

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Statistical Considerations for Immunohistochemistry Panel Development after Gene Expression Profiling of Human Cancers Rebecca A. Betensky, Catherine.

Figure 2 The US Centers for Disease Control and

Figure 2 Exosome composition

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

In vivo imaging of molecular-genetic targets for cancer therapy

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Bad-metal behaviour and electron correlations

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Towards precision PRRT for neuroendocrine tumours

Figure 3 Transcriptome studies performed in the target

Figure 1 Biosimilar development process

Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease Andrew E. Hendifar,

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Surgical step-up approach

Figure 3 Algorithm for the determination of the clinical

Figure 1 Exosomes with siRNAs targeting

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Nat. Rev. Urol. doi: /nrurol

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 4 Functional luminal imaging probe

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Representative barium defecography images

Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease Geoffrey M. Graeber, MD*, Naresh.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

with broad-spectrum antibiotics

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Systems biological model of IBS

Orthotopic lung cancer mouse model.

Figure 1 Cancer stem cell plasticity and stem cell homeostasis in the gut Figure 1 | Cancer stem cell plasticity and stem cell homeostasis in the gut.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Nicholas W. Choong, MD, Robert S. Hellman, MD

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

OBP-401 precisely labels orthotopic lung cancer.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

CT (left of images) showing calcified areas and PET (right of images) scans showing increased FDG-PET metabolic activity in the mediastinal mass (A) and.

(A) Na18F PET images (maximum-intensity projection).

GM-CSF is required for CA-MSC–induced tumor metastasis.

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Presentation transcript:

Figure 4 PET imaging in experimental pancreatic cancer Figure 4 | PET imaging in experimental pancreatic cancer. a | Correlative imaging of orthotopically transplanted BxPC3 pancreatic tumour cells expressing a luciferase reporter gene. Bioluminescent optical imaging demonstrated the presence of tumours (T) in the area of surgical transplantation. b | MRI validated the observed tumour presence from bioluminescent optical imaging. c | The co-registration of 18F-FDG PET and CT (left panel) and planar sections of 18F-FDG PET only (right panel) displayed minimal tumour detection of the tracer with a high uptake in highly metabolic tissues: for instance, the heart (H) d | Acquired 89Zr-5B1 PET image of the same mouse co-registered with CT exhibited exceptional tumour detection of the xenografts of BxPC3 tumour cells expressing a luciferase reporter gene. B, bladder. This research was adapted from the Journal of Nuclear Medicine111. Viola-Villegas, N. T. et al. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med 2013; 54:1876–1882. © by the Society of Nuclear Medicine and Molecular Imaging, Inc. This research was adapted from the Journal of Nuclear Medicine111. Viola-Villegas, N. T. et al. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med 2013; 54:1876–1882. © by the Society of Nuclear Medicine and Molecular Imaging, Inc. Dimastromatteo, J. et al. (2016) Imaging in pancreatic disease Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.144